Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

  • September 3, 2026

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.

Leave A Comment

Fields (*) Mark are Required